Synmosa Biopharma (Taiwan) Today
| 4114 Stock | TWD 34.10 0.20 0.58% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Synmosa Biopharma is selling for under 34.10 as of the 3rd of December 2024; that is 0.58% down since the beginning of the trading day. The stock's lowest day price was 34.1. Synmosa Biopharma has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Synmosa Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. The company has 327.14 M outstanding shares. More on Synmosa Biopharma
Moving together with Synmosa Stock
Moving against Synmosa Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Synmosa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Synmosa Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Synmosa Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Synmosa Biopharma (4114) is traded on Taiwan OTC Exchange in Taiwan and employs 16 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 15.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Synmosa Biopharma's market, we take the total number of its shares issued and multiply it by Synmosa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Synmosa Biopharma operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 327.14 M outstanding shares.
Synmosa Biopharma has accumulated about 1.28 B in cash with 444.29 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
Check Synmosa Biopharma Probability Of Bankruptcy
Ownership AllocationSynmosa Biopharma shows a total of 327.14 Million outstanding shares. Synmosa Biopharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Synmosa Ownership Details
Synmosa Biopharma Risk Profiles
Although Synmosa Biopharma's alpha and beta are two of the key measurements used to evaluate Synmosa Biopharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.4719 | |||
| Standard Deviation | 0.7572 | |||
| Variance | 0.5734 | |||
| Risk Adjusted Performance | (0.16) |
Synmosa Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Synmosa Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Synmosa Biopharma Corporate Management
Elected by the shareholders, the Synmosa Biopharma's board of directors comprises two types of representatives: Synmosa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synmosa. The board's role is to monitor Synmosa Biopharma's management team and ensure that shareholders' interests are well served. Synmosa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synmosa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChihHui Lin | GM, Chairman | Profile | |
| Zen Young | Marketing HP | Profile | |
| Hongqin Bai | Sr Officer | Profile | |
| Banson Lin | Sr Distributors | Profile | |
| JiaXin Zhang | VP | Profile | |
| HungChin Pai | VP Officer | Profile |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.